U
Menu
M
Donate

LQTS Study

Clinical Study for Long QT Syndrome Types 2 & 3

This trial has completed enrollment. Stay tuned for updates as this trial moves to Phase 3.

Phase 2
Sponsor: Thryv Therapeutics

Thryv Therapeutics Inc. is conducting a clinical study to evaluate the safety and tolerability of an investigational medicine, LQT-1213, in people with Long QT Syndrome Type 2 or Type 3.

Basic Eligibility Criteria

We are looking for male and female participants between the ages 18-60 that have a diagnosis of Long QT Syndrome Type 2 or Type 3.

6-day commitment including travel time. Study will occur in a monitored clinical unit. We will work with your schedule to determine optimal timing.

All participants in the study will be compensated a stipend for their time. All travel costs will be paid for as well as hotel and food costs for a companion.

The information contained herein is being made available as a public service by the SADS Foundation (SADS). No posted information or material provided is intended to constitute medical or professional advice. SADS makes no representations or warranties, either express or implied, as to the accuracy of any posted information and assumes no responsibility for any errors or omissions contained therein. SADS makes no representations or warranties, either express or implied, that any products or services adhere to or satisfy any standards or requirements that may be applicable to such product or service. Furthermore, no warranty, express or implied, is created by providing information and does not in any way constitute an endorsement by SADS. No one shall be entitled to claim detrimental reliance on any views or information, or to claim any duty on the part of SADS to update posted information. In no event shall SADS be held liable to you or anyone else for any decision made or action taken in reliance on such information or views.